Funding for this research was provided by:
Merck Sharp and Dohme
Received: 14 July 2022
Accepted: 17 October 2022
First Online: 24 January 2023
: This study received human subjects approval from the Indiana University School of Medicine Institutional Review Board (IRB no. 2011632512). The Indiana University School of Medicine IRB approved a waiver of informed consent given the retrospective cohort design. All study activities and research methods were performed in accordance with the relevant guidelines and regulations.
: Not applicable.
: FC and RKK are employees of Merck Sharp &Dohme Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, who may own stock and/or hold stock options in Merck & Co., Inc., Rahway, NJ, USA. CS receives consulting fees from Regenstrief.